Use of the Selective Cytopheretic Device in Critically Ill Children.

ABSTRACT:

Introduction

Critically ill children with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT) are at increased risk of death. The selective cytopheretic device (SCD) promotes an immunomodulatory effect when circuit ionized calcium (iCa²⁺) is maintained at <0.40 mmol/l with regional citrate anticoagulation (RCA). In a randomized trial of adult patients on CRRT, those treated with the SCD maintaining an iCa²⁺ <0.40 mmol/l had improved survival/dialysis independence. We conducted a US Food and Drug Administration (FDA)-sponsored study to evaluate safety and feasibility of the SCD in 16 critically ill children.

Methods

Four pediatric intensive care units (ICUs) enrolled children with AKI and multiorgan dysfunction receiving CKRT

SUBMITTER: Goldstein SL 

PROVIDER: S-EPMC7938071 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature